Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Lisa Shirreff"'
Autor:
Payton A.-B. Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, Shaogeng Tang, Prabhu S. Arunachalam, Mengyun Hu, Ozan S. Kumru, Mary Kate Morris, Jane Fontenot, Lisa Shirreff, Jonathan Do, Ya-Chen Cheng, Gayathri Vasudevan, Mark B. Feinberg, Francois J. Villinger, Carl Hanson, Sangeeta B. Joshi, David B. Volkin, Bali Pulendran, Peter S. Kim
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs). Here, w
Externí odkaz:
https://doaj.org/article/4b2711e833a84864a890be327d293be9
Autor:
Payton A.-B. Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, Shaogeng Tang, Prabhu S. Arunachalam, Mengyun Hu, Ozan S. Kumru, Mary Kate Morris, Jane Fontenot, Lisa Shirreff, Jonathan Do, Ya-Chen Cheng, Gayathri Vasudevan, Mark B. Feinberg, Francois J. Villinger, Carl Hanson, Sangeeta B. Joshi, David B. Volkin, Bali Pulendran, Peter S. Kim
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/dbf7e69ac4e540d2a86ef987b054a206
Autor:
Giulia Calenda, Ines Frank, Géraldine Arrode-Brusés, Amarendra Pegu, Keyun Wang, James Arthos, Claudia Cicala, Kenneth A Rogers, Lisa Shirreff, Brooke Grasperge, James L Blanchard, Stephanie Maldonado, Kevin Roberts, Agegnehu Gettie, Francois Villinger, Anthony S Fauci, John R Mascola, Elena Martinelli
Publikováno v:
PLoS Pathogens, Vol 15, Iss 5, p e1007776 (2019)
VRC01 protects macaques from vaginal SHIV infection after a single high-dose challenge. Infusion of a simianized anti-α4β7 mAb (Rh-α4β7) just prior to, and during repeated vaginal exposures to SIVmac251 partially protected macaques from vaginal S
Externí odkaz:
https://doaj.org/article/56f99e9871a14c77a113d5c201dca31e
Autor:
Shankar Subramaniam, David Veesler, Lauren Carter, David Novack, Claire Sydeman, Jane Fontenot, Douglas E. Ferrell, Galit Alter, Robbert van der Most, Robert L. Coffman, Elizabeth Kepl, Mary Jane Navarro, Alexander G. White, Ching-Lin Hsieh, Kenneth S. Plante, Francois Villinger, Katharina Röltgen, Prabhu S. Arunachalam, Alexandra C. Walls, Jason S. McLellan, Lisa Shirreff, Rino Rappuoli, Sally Shin, Venkata Viswanadh Edara, Jessica A. Plante, Brooke Fiala, Stephanie Fischinger, Chunfeng Li, Caroline Atyeo, Matthew J. Gorman, Chad J. Roy, Scott D. Boyd, Bali Pulendran, Kasi E. Russell-Lodrigue, Skye Spencer, Xiaoying Shen, Shakti Gupta, Derek T. O'Hagan, Pyone P. Aye, Meera Trisal, Neil P. King, JoAnne L. Flynn, Nadia A. Golden, Marcos C. Miranda, Michael E. P. Murphy, John C. Kraft, Mehul S. Suthar, Lilin Lai, Jason Dufour, Rudolph Bohm, Deleah Pettie, Lara A. Doyle-Meyers, David C. Montefiori, Christopher Monjure, Kenneth A. Rogers, Samuel Wrenn, Harry Kleanthous, Nicholas J. Maness, Jay Rappaport, Alex Lee Zhu, Natalie Brunette
Publikováno v:
Nature. 594:253-258
The development of a portfolio of COVID-19 vaccines to vaccinate the global population remains an urgent public health imperative1. Here we demonstrate the capacity of a subunit vaccine, comprising the SARS-CoV-2 spike protein receptor-binding domain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::442cf7639520da9f4126cb4a6dcc72fb
https://doi.org/10.1038/s41586-021-03530-2
https://doi.org/10.1038/s41586-021-03530-2
Autor:
Prabhu S. Arunachalam, Yupeng Feng, Usama Ashraf, Mengyun Hu, Venkata Viswanadh Edara, Veronika I. Zarnitsyna, Pyone Pyone Aye, Nadia Golden, Kristyn W. M. Green, Breanna M. Threeton, Nicholas J. Maness, Brandon J. Beddingfield, Rudolf P. Bohm, Jason Dufour, Kasi Russell-Lodrigue, Marcos C. Miranda, Alexandra C. Walls, Kenneth Rogers, Lisa Shirreff, Douglas E Ferrell, Nihar R. Deb Adhikary, Jane Fontenot, Alba Grifoni, Alessandro Sette, Derek T. O’Hagan, Robbert Van Der Most, Rino Rappuoli, Francois Villinger, Harry Kleanthous, Jay Rappaport, Mehul S. Suthar, David Veesler, Taia T. Wang, Neil P. King, Bali Pulendran
SummaryDespite the remarkable efficacy of COVID-19 vaccines, waning immunity, and the emergence of SARS-CoV-2 variants such as Omicron represents a major global health challenge. Here we present data from a study in non-human primates demonstrating d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98b7f67bea5ccdd07a3aed0a9846fba3
https://doi.org/10.1101/2022.03.18.484950
https://doi.org/10.1101/2022.03.18.484950
Autor:
Alexandra C. Walls, Laura A. VanBlargan, Kai Wu, Angela Choi, Mary Jane Navarro, Diana Lee, Laura Avena, Daniela Montes Berrueta, Minh N. Pham, Sayda Elbashir, Marcos C. Miranda, Elizabeth Kepl, Max Johnson, Alyssa Blackstone, Kaitlin Sprouse, Brooke Fiala, Megan A. O’Connor, Natalie Brunette, Prabhu S. Arunachalam, Lisa Shirreff, Kenneth Rogers, Lauren Carter, Deborah H. Fuller, Francois Villinger, Bali Pulendran, Michael S. Diamond, Darin K. Edwards, Neil P. King, David Veesler
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has led to the development of a large number of vaccines, several of which are now approved for use in humans. Understanding vaccine-elicited antibody responses aga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b41db2620d879ef9b5d36cae1917cb60
https://doi.org/10.1101/2022.02.07.479468
https://doi.org/10.1101/2022.02.07.479468
Autor:
Bali Pulendran, Allison J. Greaney, Max Johnson, Brooke Fiala, Ralph S. Baric, Jesse D. Bloom, Tyler N. Starr, Elizabeth Kepl, Rashmi Ravichandran, David Veesler, Roland Tisch, Mary-Jane Navarro, Kenneth A. Rogers, Kaitlin R. Sprouse, Kelly D. Smith, Natalie Brunette, Megan A. O'Connor, M. Alejandra Tortorici, Douglas E. Ferrell, Davide Corti, Prabhu S. Arunachalam, Timothy P. Sheahan, Samuel Wrenn, Robbert van der Most, Sarah R. Leist, Lisa Shirreff, Harry Kleanthous, Marcos C. Miranda, Alyssa Blackstone, Claire Sydeman, Francois Villinger, Jason S. McLellan, Deleah Pettie, David R. Martinez, Cassandra Ogohara, Minh N. Pham, Lauren Carter, Wesley C. Van Voorhis, Deborah H. Fuller, Samantha K Zepeda, Alexandra Schäfer, Sasha W Tilles, Matthew Clark, Alexandra C. Walls, Rino Rappuoli, John E. Bowen, Neil P. King, Derek T. O'Hagan, Ching-Lin Hsieh
Publikováno v:
Cell
bioRxiv
article-version (status) pre
article-version (number) 1
bioRxiv
article-version (status) pre
article-version (number) 1
Understanding vaccine-elicited protection against SARS-CoV-2 variants and other sarbecoviruses is key for guiding public health policies. We show that a clinical stage multivalent SARS-CoV-2 spike receptor-binding domain nanoparticle vaccine (RBD-NP)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98c5d8df56cfa58183e50431d4e430ba
https://pubmed.ncbi.nlm.nih.gov/34619077
https://pubmed.ncbi.nlm.nih.gov/34619077
Autor:
Bali Pulendran, David Novack, Deleah Pettie, Jay Rappaport, Xiaoying Shen, Ching-Lin Hsieh, Rudolph B Bohm, Alexandra C. Walls, Elizabeth Kepl, David Veesler, Shankar Subramaniam, Rino Rappuoli, Harry Kleanthous, Claire Sydeman, Derek T O Hagan, Alex Lee Zhu, JoAnne L. Flynn, Robbert van der Most, Christopher Monjure, Kenneth S. Plante, Francois Villinger, Prabhu S. Arunachalam, Nicholas J. Maness, Pyone P. Aye, Sally Shin, Matthew J. Gorman, Natalie Brunette, Michael E. P. Murphy, Lilin Lai, Scott D. Boyd, Caroline Atyeo, Katharina Röltgen, Venkata Viswanadh Edara, Robert L Coffman, Chad J. Roy, Kasi E. Russell-Lodrigue, David C. Montefiori, Nadia A. Golden, Meera Trisal, Jessica A. Plante, John C. Kraft, Mehul S. Suthar, Jason Dufour, Kenneth A. Rogers, Marcos C. Miranda, Lisa Shirreff, Brooke Fiala, Samuel Wrenn, Lara Doyle-Meyer, Shakti Gupta, Douglas E. Ferrell, Jane Fontenot, Jason S. McLellan, Lauren Carter, Mary Jane Navarro, Alexander G. White, Stephanie Fischinger, Neil P. King, Galit Alter, Chunfeng Li
Publikováno v:
bioRxiv : the preprint server for biology.
The development of a portfolio of SARS-CoV-2 vaccines to vaccinate the global population remains an urgent public health imperative. Here, we demonstrate the capacity of a subunit vaccine under clinical development, comprising the SARS-CoV-2 Spike pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7d21f226ab76efebd2264b0b460ab88
https://pubmed.ncbi.nlm.nih.gov/33873199
https://pubmed.ncbi.nlm.nih.gov/33873199
Autor:
Prabhu S, Arunachalam, Alexandra C, Walls, Nadia, Golden, Caroline, Atyeo, Stephanie, Fischinger, Chunfeng, Li, Pyone, Aye, Mary Jane, Navarro, Lilin, Lai, Venkata Viswanadh, Edara, Katharina, Röltgen, Kenneth, Rogers, Lisa, Shirreff, Douglas E, Ferrell, Samuel, Wrenn, Deleah, Pettie, John C, Kraft, Marcos C, Miranda, Elizabeth, Kepl, Claire, Sydeman, Natalie, Brunette, Michael, Murphy, Brooke, Fiala, Lauren, Carter, Alexander G, White, Meera, Trisal, Ching-Lin, Hsieh, Kasi, Russell-Lodrigue, Christopher, Monjure, Jason, Dufour, Skye, Spencer, Lara, Doyle-Meyers, Rudolph P, Bohm, Nicholas J, Maness, Chad, Roy, Jessica A, Plante, Kenneth S, Plante, Alex, Zhu, Matthew J, Gorman, Sally, Shin, Xiaoying, Shen, Jane, Fontenot, Shakti, Gupta, Derek T, O'Hagan, Robbert, Van Der Most, Rino, Rappuoli, Robert L, Coffman, David, Novack, Jason S, McLellan, Shankar, Subramaniam, David, Montefiori, Scott D, Boyd, JoAnne L, Flynn, Galit, Alter, Francois, Villinger, Harry, Kleanthous, Jay, Rappaport, Mehul S, Suthar, Neil P, King, David, Veesler, Bali, Pulendran
Publikováno v:
bioRxiv
The development of a portfolio of SARS-CoV-2 vaccines to vaccinate the global population remains an urgent public health imperative. Here, we demonstrate the capacity of a subunit vaccine under clinical development, comprising the SARS-CoV-2 Spike pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b0221be8b7aa6f9e1845cc9a754c8f22
https://pubmed.ncbi.nlm.nih.gov/33594366
https://pubmed.ncbi.nlm.nih.gov/33594366
Autor:
Tanner DuCote, Phani Rama Krishna Behra, Don G. Ennis, Sarbashis Das, Lisa Shirreff, Martin Cheramie, B. M. Fredrik Pettersson, Santanu Dasgupta, Amrita Mallick, Leif A. Kirsebom, Malavika Ramesh
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-1 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-1 (2020)
Mycobacterium marinum is the causative agent for the tuberculosis-like disease mycobacteriosis in fish and skin lesions in humans. Ubiquitous in its geographical distribution, M. marinum is known to occupy diverse fish as hosts. However, information
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23996bc9cf71effbb4a5be53f7b9eca2
http://europepmc.org/articles/PMC7078255
http://europepmc.org/articles/PMC7078255